Gonadorelin is a synthetic form of Gonadotropin-releasing hormone, a naturally occurring decapeptide produced by the hypothalamus that regulates reproductive function by stimulating the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Its history traces back to the early 1970s, when scientists Andrew V. Schally and Roger Guillemin independently isolated and characterized GnRH, a breakthrough that earned them the 1977 Nobel Prize in Physiology or Medicine. Following this discovery, synthetic analogs like gonadorelin were developed for clinical use, primarily in diagnosing and treating disorders of the reproductive endocrine system such as delayed puberty and infertility. Over time, gonadorelin also became important in assisted reproductive technologies and endocrine research, offering a controlled way to assess pituitary function and hormonal regulation.
BRAND NAMES
Factrel: Primarily used for diagnostic evaluation of pituitary gland function.
Lutrepulse: Previously used to induce ovulation, typically administered via a subcutaneous infusion pump.
Kryptocur: A nasal preparation that was once used in the treatment of Cryptorchidism.
Other international brands: Lutrelef, HRF, Fertagyl, Relisorm L, and Luforan are marketed in various countries for similar therapeutic or diagnostic purposes.
MECHANISM OF ACTION
Gonadorelin is a synthetic decapeptide that functions as an agonist of Gonadotropin-releasing hormone, closely imitating the action of the natural hormone. It acts on pituitary gonadotroph cells by binding to GnRH receptors, activating the phospholipase C signaling pathway and leading to the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn promote the production of reproductive steroids in the gonads. For therapeutic purposes such as ovulation induction or infertility treatment, it needs to be delivered in a pulsatile pattern to replicate normal physiological secretion; in contrast, continuous administration results in receptor desensitization and suppression of gonadotropin release.
PHARMACOKINETICS
Absorption: After intravenous administration, availability is immediate; it is also quickly absorbed when given via subcutaneous or intramuscular injection.
Distribution: It has an approximate volume of distribution of 10–15 L.
Metabolism: It is rapidly broken down in the plasma into smaller, inactive peptide fragments.
Elimination: The inactive metabolites are mainly excreted through the urine.
PHARMACODYNAMICS
Gonadorelin, an agonist of Gonadotropin-releasing hormone receptors, stimulates the anterior pituitary gland to produce and release luteinizing hormone (LH) and, to a lesser extent, follicle-stimulating hormone (FSH). By imitating the natural pulsatile secretion of GnRH, it helps regulate reproductive steroid production, promotes ovulation in females, and supports spermatogenesis in males.
DOSAGE AND ADMINISTRATION
Route of administration: Given by intravenous (IV), subcutaneous (SC), or intramuscular (IM) injection; pulsatile SC infusion may be used for physiological hormone replacement.
Diagnostic use: A single IV bolus dose (commonly around 100 mcg in adults) is administered to assess pituitary release of LH and FSH.
Ovulation induction / infertility treatment: Administered in a pulsatile manner (e.g., small doses every 60–120 minutes) using an infusion pump to mimic natural Gonadotropin-releasing hormone secretion.
Pediatric use: Doses are adjusted based on body weight and clinical indication, particularly for evaluating delayed puberty.
Duration of therapy: Depends on the indication—short-term for diagnostic testing and longer, carefully monitored regimens for fertility treatment.
Monitoring: Hormone levels (LH, FSH, and sex steroids) and clinical response should be regularly assessed during therapy.
FOOD INTERACTIONS
Gonadorelin generally does not have any known interactions with food because it is administered by injection (intravenous or subcutaneous) rather than taken orally. However, patients are advised to consult their healthcare provider about the use of alcohol or tobacco while on treatment, as these may potentially influence its effects.
DRUG INTERACTIONS
Gonadorelin has relatively few well-documented drug interactions, but its effects can be influenced by other medications that act on the endocrine system. Concurrent use with hormonal therapies such as estrogens, progesterone, or androgens may modify the pituitary response to Gonadotropin-releasing hormone, potentially affecting both diagnostic and therapeutic outcomes. Similarly, the use of other GnRH agonists or antagonists can either enhance or suppress gonadotropin release depending on the treatment regimen. Drugs that affect dopamine pathways, including dopamine agonists or antagonists, may indirectly alter pituitary hormone secretion, while high doses of corticosteroids can suppress pituitary responsiveness. Overall, although significant interactions are uncommon, careful monitoring is recommended when gonadorelin is used alongside other hormone-related medications.
CONTRAINDICATIONS
Gonadorelin (gonadorelin acetate, Lutrepulse) is contraindicated in patients with known hypersensitivity to Gonadotropin-releasing hormone or its analogs, as well as during pregnancy and breastfeeding. It is also avoided in individuals with untreated hormone-dependent tumors. In addition, it should not be used in women with ovarian cysts or other conditions that may be aggravated by reproductive hormones. Its use is generally not recommended in children.
SIDE EFFECTS
Injection site reactions: Pain, redness, swelling, or irritation at the site of administration (IV, IM, or SC).
Flushing and warmth: Temporary feelings of heat or facial flushing.
Headache: Mild to moderate headaches may occur during therapy.
Nausea or gastrointestinal discomfort: Occasionally reported after administration.
Hormonal effects: Changes in Gonadotropin-releasing hormone activity may lead to breast tenderness, mood changes, or altered menstrual patterns.
Dizziness or fatigue: Some patients may experience lightheadedness or tiredness.
Rare effects: Allergic reactions such as rash, itching, or hypersensitivity (rare but possible).
OVERDOSE
Overdose of gonadorelin is uncommon and is not usually associated with severe acute toxicity because of normal hormonal feedback regulation in the body. However, excessive dosing may result in pituitary overstimulation, potentially leading to the development of multiple ovarian follicles or increased sensitivity to side effects. If an overdose is suspected, medical attention should be sought promptly, especially if symptoms such as severe abdominal pain or breathing difficulties occur.
TOXICITY
Gonadorelin, an agonist of Gonadotropin-releasing hormone, has low toxicity at therapeutic doses, but it may still lead to significant adverse effects. These can include ovarian hyperstimulation syndrome (OHSS), hypersensitivity reactions up to anaphylaxis, and rare but serious pituitary-related complications. More commonly reported effects are headache, nausea, abdominal pain, and reactions at the injection site. It also carries a risk of fetal harm during pregnancy and is contraindicated in patients with hormone-dependent tumors.
